Early warnings for cancer drug trials.

When a drug trial is in trouble, companies rarely say so right away. But clues show up first. Tremor watches for them and gives every trial a worry score from 0 to 100.

cancer trials watched: 1,669
public companies: 196
last checked: on Nov 9, 2026

Biggest worries right now

Trials with the most warning signs. A high score is not a prediction.

85Tremor
NVSStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
The trial was stopped early, so it goes straight to red
33Calm
ARTVAB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Announced layoffs or restructuring + 2 more
22Calm
VSTMA Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
A key executive is leaving + 1 more
18Calm
IONSGOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Main results were due Apr 2024, none posted yet + 1 more
18Calm
IONSA Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Main results were due Jun 2025, none posted yet + 1 more
16Calm
PDSBStudy of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
Main results were due May 2025, none posted yet + 1 more
16Calm
ANLThe BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Main results were due Nov 2025, none posted yet + 1 more
16Calm
AURAPhase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Main results were due Apr 2024, none posted yet + 1 more

Latest changes

Show minor changes too

NVSStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer85Tremor
The trial was stopped early.
Novartis has stopped a late-stage study of a lung cancer drug early, after it had been running and planned for 95 patients. The company hasn't said why it stopped. Investors watch a change like this because an early stop in a late-stage trial can sometimes signal that the drug is not working as hoped, or that it may be causing problems, and that could affect the company's future sales. The same kind of stop can also happen for ordinary reasons, such as slow patient enrollment, shifts in company priorities, or results that are not clear enough to justify continuing, so this change alone doesn't prove the drug has failed.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
RIGLStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)10Calm
Pushed back the final finish date by about 24 months: Dec 2026 → Dec 2028.
The company moved the expected finish date for its study of R289 in people with lower-risk myelodysplastic syndromes (a group of blood disorders) from December 2026 to December 2028, a delay of about 24 months. Investors watch changes like this because a longer timeline can hint that patients are joining more slowly than planned or that the study design is being reworked, which could mean results come later and cost more. A date moving can also have ordinary causes, such as scheduling adjustments or paperwork, and the company hasn't said why it changed, so this alone doesn't show whether the study is in trouble.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
RIGLStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)10Calm
Pushed back the main results date by about 16 months: Aug 2026 → Dec 2027.
A drug study from Rigel Pharmaceuticals has pushed back the date when its main results are expected, from August 2026 to December 2027, a delay of about 16 months. Investors often watch changes like this because a delay can sometimes mean the study is taking longer than planned, perhaps due to trouble finding or keeping patients, or because the company is adjusting how it will judge the drug, and either could point to a weaker outlook than expected. But schedules shift for many ordinary reasons, such as slower patient sign-ups or simple planning updates, and the company hasn't said why this one moved, so a later date on its own doesn't prove anything about the drug or the company.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
JAZZA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC12Calm
Pushed back the final finish date by about 18 months: Apr 30, 2028 → Nov 4, 2029.
Spotted on Nov 6, 2026
JAZZA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC12Calm
Pushed back the main results date by about 18 months: Jan 31, 2028 → Aug 4, 2029.
Jazz Pharmaceuticals pushed back the date when the main results from its lung cancer study are expected, from 2028-01-31 to 2029-08-04, about 18 months later. The study is a mid-stage test (called Phase 2) that is still enrolling patients, meaning it is still signing up people to take part, with 50 planned. Investors watch a delay like this because it can sometimes signal that enrollment or the study itself is running slower than planned, but a date change can also come from routine scheduling, and the company hasn't said why it moved. On its own, this change doesn't prove that anything is wrong with the study.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
AMGNStudy Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab12Calm
Pushed back the final finish date by about 18 months: Sep 30, 2028 → Apr 2, 2030.
Amgen's late-stage study (Phase 3, a test of whether a treatment works in a larger group of patients) has pushed its final finish date from 2028-09-30 to 2030-04-02, about 18 months later, and it is no longer signing up new patients. A later finish date can be a worry for investors because it may mean the study is moving more slowly than planned, which could point to problems with the trial itself. But delays also happen for ordinary reasons, such as scheduling or paperwork, and the company hasn't said why this one moved, so the change alone doesn't prove anything.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
AMGNStudy Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab12Calm
Pushed back the main results date by about 33 months: Jul 5, 2027 → Apr 2, 2030.
Amgen pushed back the expected date for the main results of a late-stage study of its lung cancer drug tarlatamab, from July 2027 to April 2030, which is about 33 months later. Investors often watch changes like this because a delayed result can signal that a trial is taking longer than planned, which may point to slower progress or problems with the study. The change is an ordinary one, though, and companies move these dates for many reasons, so by itself it doesn't show that anything is wrong with the drug or the trial. The company hasn't said why the date moved.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026
GLUEStudy of Oral MRT-2359 in Selected Cancer Patients13Calm
Pushed back the main results date by about 7 months: May 2026 → Dec 2026.
The company is Monte Rosa Therapeutics, which trades as GLUE, and it is testing an oral cancer drug called MRT-2359 in a Phase 1/2 trial (an early-stage study that checks safety and looks for signs the drug works). The trial has stopped signing up new patients but is still running, and the date for its main results has moved from May 2026 to December 2026, about 7 months later. Investors watch for this kind of change because a delayed results date can hint that the study is taking longer than planned, which might point to slower enrollment, extra follow-up, or problems in the data. Still, a date moving is also common for ordinary reasons, such as scheduling changes or a decision to collect more information, so by itself it doesn't show that anything is wrong with the drug or the study.
AI-written from the facts above · tap the trial to read more
Spotted on Nov 6, 2026

Hiding routine edits like “started signing up patients” and small date tweaks.